Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision

Intern Med J. 2019 Aug;49(8):1054-1055. doi: 10.1111/imj.14386.

Authors

Nicholas Lintzeris^{1

2

3}, Thomas Santo Jr³, Suzanne Nielsen^{3

4}, Louisa Degenhardt³, Gabrielle Campbell³

Affiliations

¹ Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, New South Wales, Australia.
² Division Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia.
³ National Drug and Alcohol Centre, University of New South Wales, Sydney, New South Wales, Australia.
⁴ Monash Addiction Research Centre, Monash University, Melbourne, Victoria, Australia.

No abstract available

Publication types

Letter

MeSH terms

Analgesics, Opioid / therapeutic use
Centers for Disease Control and Prevention, U.S.
Chronic Pain / drug therapy*
Drug Overdose / drug therapy*
Harm Reduction
Health Knowledge, Attitudes, Practice
Humans
Naloxone / therapeutic use*
Narcotic Antagonists / therapeutic use*
Neoplasms
United States

Substances

Analgesics, Opioid
Narcotic Antagonists
Naloxone

Grants and funding